Royalty Pharma plcRPRX
NasdaqGS•Healthcare•Biotechnology
Analyze revenue and earnings growth — the core drivers of long-term shareholder returns.
TTM revenue reached $2.44B, growing 7.8% year-over-year. TTM net income stood at $827.29M (24.3% contraction). Quarterly EBITDA was $563.04M and operating income was $563.04M. Consistent revenue and earnings growth are the primary drivers of long-term shareholder returns. Analyze RPRX growth trends across revenue, EBITDA, operating income, and net income.
Revenue and earnings growth across quarters